<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">39432702</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK608181</ArticleId></ArticleIdList><Book><Publisher><PublisherName>Therapeutics Initiative</PublisherName><PublisherLocation>Vancouver (BC)</PublisherLocation></Publisher><BookTitle book="theraletter">Therapeutics Letter</BookTitle><PubDate><Year>1994</Year></PubDate><BeginningDate><Year>1994</Year></BeginningDate><AuthorList Type="editors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author></AuthorList></Book><LocationLabel Type="chapter">Letter 149</LocationLabel><ArticleTitle book="theraletter" part="TL-149">How useful is Paxlovid&#x2122; in 2024?</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText><b>Background:</b> In 2024 the risk of hospitalization or death due to COVID-19 is low for most people under age 80 in British Columbia (BC). However, for those at high risk of complications, the antiviral drug combination nirmatrelvir-ritonavir (NMV-r, marketed as Paxlovid&#x2122;) has shown promise in reducing the composite risk of hospitalization and death from COVID-19. <b>Methods:</b> We evaluated the effectiveness of NMV-r based on data from 3 randomized controlled trials conducted by Pfizer and an observational study conducted by the Therapeutics Initiative in British Columbia. In addition to the impact of NMV-r on COVID-19-related hospitalization or death, we considered the impact of vaccination status on the drug&#x2019;s effectiveness. <b>Results:</b> The EPIC-HR trial showed a significant reduction in hospitalization and death in high-risk, unvaccinated patients during 2021. In contrast, the 2021&#x2013;2022 EPIC-SR trial found no benefit for lower-risk, vaccinated patients. The BC observational study found statistically significant risk reductions in high-risk groups, but not in an expanded eligibility group. NMV-r does not affect symptom duration or prevent transmission and is not known to prevent long-COVID. <b>Conclusions:</b> NMV-r may benefit high-risk COVID-19 patients, but it offers little advantage for lower-risk, vaccinated individuals. As Paxlovid&#x2122; will cost Canadians about $1,400 per treatment, cost-effectiveness is a significant consideration. The ongoing <i>PANORAMIC</i> and <i>CanTreatCOVID</i> clinical trials may provide further insights into NMV-r&#x2019;s long-term effects on COVID-19 and on healthcare utilization. [Image: see text]</AbstractText><CopyrightInformation>Copyright &#xa9; 1994 - 2022 Therapeutics Initiative, University of British Columbia.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s1">How useful is Paxlovid&#x2122; in 2024?</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s2">Summary and Conclusions</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s3">Evidence has emerged gradually as to who is most likely to benefit from NMV-r for COVID-19</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s4">What can we learn from the EPIC trials?</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s5">Observational study of NMV-r in BC: final results</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s6">What can we tell patients who contract COVID-19?</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s7">Will more information from RCTs be forthcoming?</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.s8">Is NMV-r therapy worth the cost?</SectionTitle></Section><Section><SectionTitle book="theraletter" part="TL-149" sec="TL-149.rl1">References</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">Antiviral Agents</Keyword><Keyword MajorTopicYN="N">Cost-Benefit Analysis</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Combination Drug Therapy</Keyword><Keyword MajorTopicYN="N">Nirmatrelvir</Keyword><Keyword MajorTopicYN="N">Paxlovid</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trials as Topic</Keyword><Keyword MajorTopicYN="N">Risk Factors</Keyword><Keyword MajorTopicYN="N">Ritonavir</Keyword></KeywordList><ContributionDate><Year>2024</Year><Month>4</Month></ContributionDate><ReferenceList><Reference><Citation>Therapeutics Initiative. Paxlovid in British Columbia: Interim real-world analysis. Therapeutics Letter
141, January&#x2013;February
2023. https://ti.ubc.ca/letter141</Citation></Reference><Reference><Citation>Food and Drug Administration. FDA briefing document: Antimicrobial Drugs Advisory Committee meeting, March
16, 2023. https://www.fda.gov/media/166197/download Errata: https://www.fda.gov/media/166198/download</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. . Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine. 2022; 386(15):1397&#x2013;1408. DOI: 10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer. Pfizer Reports Additional Data on PAXLOVID&#x2122; Supporting Upcoming New Drug Application Submission to US FDA. June
14, 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting</Citation></Reference><Reference><Citation>US National Library of Medicine. Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). https://classic.clinicaltrials.gov/ct2/show/results/NCT05011513</Citation></Reference><Reference><Citation>Hammond J, Fountaine RJ, Yunis C, et al. . Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. New England Journal of Medicine. 2024; 390(13):1186&#x2013;1195. DOI: 10.1056/NEJMoa2309003</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2309003</ArticleId><ArticleId IdType="pmc">PMC11156287</ArticleId><ArticleId IdType="pubmed">38598573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer. Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID&#x2122; for Post-Exposure Prophylactic Use. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study</Citation></Reference><Reference><Citation>US National Library of Medicine. A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection. https://classic.clinicaltrials.gov/ct2/show/results/NCT05047601</Citation></Reference><Reference><Citation>Pfizer. EPIC-HR Protocol C4671005: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine. 2022; 386(15) https://nejm.org/doi/suppl/10.1056/NEJMoa2118542/suppl_file/nejmoa2118542_protocol.pdf</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542/suppl_file/nejmoa2118542_protocol.pdf</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer. EPIC-SR Protocol C4671002: Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. New England Journal of Medicine
2024; 390(13) https://www.nejm.org/doi/suppl/10.1056/NEJMoa2309003/suppl_file/nejmoa2309003_protocol.pdf</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2309003/suppl_file/nejmoa2309003_protocol.pdf</ArticleId><ArticleId IdType="pmc">PMC11156287</ArticleId><ArticleId IdType="pubmed">38598573</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormuth CR, Kim JD, Fisher A, et al. . Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications. JAMA Network Open 2023; 6(10):e2336678. DOI: 10.1001/jamanetworkopen.2023.36678</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.36678</ArticleId><ArticleId IdType="pmc">PMC10546233</ArticleId><ArticleId IdType="pubmed">37782496</ArticleId></ArticleIdList></Reference><Reference><Citation>BC COVID Therapeutics Committee (CTC). Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19. November
2023.  Update. http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/ClinicalPracticeGuide_Therapeutics_MildModerateCOVID.pdf</Citation></Reference><Reference><Citation>Canadian Agency for Drugs, Technology and Health Assessment. CADTH Reimbursement Recommendation Nirmatrelvir-Ritonavir (Paxlovid&#x2122;). January
2024. https://www.cadth.ca/sites/default/files/DRR/2024/SR0808%20Paxlovid%20-%20Draft%20CADTH%20Recommendation.pdf</Citation></Reference><Reference><Citation>Skowronski DM, Kaweski SE, Irvine MA, et al. . Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada. CMAJ Canadian Medical Association Journal 2023; 195(42):E1427&#x2013;1439. DOI: 10.1503/cmaj.230721</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.230721</ArticleId><ArticleId IdType="pmc">PMC10615343</ArticleId><ArticleId IdType="pubmed">37903524</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer Canada. Paxlovid&#x2122; Product Monograph. Revised January 2, 2024. https://covid-vaccine.canada.ca/info/pdf/paxlovid-pm-en.pdf</Citation></Reference><Reference><Citation>University of Oxford. PANORAMIC: Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 in the Community. https://www.panoramictrial.org</Citation></Reference><Reference><Citation>Butler CC, Hobbs FDR, Gbinigie OA, et al. . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomized controlled trial. Lancet 2023; 401(10373):281&#x2013;293. DOI: 10.1016/S0140-6736(22)02597-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02597-1</ArticleId><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Png ME, Harris V, Grabey J, et al. . Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial. British Journal of General Practice 2024. DOI: 10.3399/BJGP.2023.0444</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGP.2023.0444</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Canada Drug and Health Product Portal. Summary of Cancellation for Molnupiravir (*Lagevrio). April
26, 2023. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1683828447298</Citation></Reference><Reference><Citation>Butler C. A clinical trial investigating novel treatments for COVID-19 in the community. ISRCTN registry. 2024. DOI: 10.1186/ISRCTN30448031</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ISRCTN30448031</ArticleId></ArticleIdList></Reference><Reference><Citation>University of Oxford. PANORAMIC trial documents. Updated: October 12, 2023. https://panoramictrial.org/for-healthcare-professionals/documentsProtocol: https://panoramictrial.org/files/protocols/panoramic_protocol_v8-0_04oct2023.pdf</Citation></Reference><Reference><Citation>Pinto A, et al. . Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID). 2024. https://cantreatcovid.org</Citation></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432702</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>